UCERIS RECTAL FOAM Rx
Generic Name and Formulations:
Budesonide 2mg; per metered dose; emulsion.
Bausch Health Companies Inc.
Indications for UCERIS RECTAL FOAM:
Induction of remission in patients with active, mild-to-moderate distal ulcerative colitis extending up to 40cm from the anal verge.
For rectal use only. Empty bowels prior to administration. Apply 1 metered dose twice daily (AM & PM) for 2 weeks, then 1 metered dose once daily (PM) for 4 weeks.
Not for oral use. Active or quiescent tuberculosis, untreated fungal, bacterial, systemic viral or parasitic infections or ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral therapies. Supplement with systemic glucocorticosteroid in surgery or other stress situations. Caution when transferring from steroids with high systemic effects; monitor. May unmask allergies previously controlled by systemic corticosteroids. Hypertension. Diabetes. Osteoporosis. Peptic ulcer. Glaucoma. Cataracts. Temporarily discontinue prior to colonoscopy bowel preparation. Moderate-to-severe hepatic impairment (Child-Pugh Class B or C): monitor for hypercorticism; consider discontinuing if occurs. Flammable. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by concomitant CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, cyclosporine, grapefruit juice); avoid.
Decreased blood cortisol, adrenal insufficiency, nausea; hypercorticism, adrenal suppression, immunosuppression, increased susceptibility to infection.
Canister—1 (14 doses); Kit—1 (2 canisters w. 28 applicators)
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage